Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome

• Status: Unknown status
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether an increase of blood haemoglobin levels through the substitution of erythropoietin during radiotherapy treatment of cervix cancer patients results in improvement for disease specific survival, tumor response and local control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• histologically proven cervix cancer (FIGO stage I-IVA)

• Age of 19-80 years

• initial blood level of hemoglobin <= 14 g/dl

• patients who gave their informed consent

Exclusion Criteria:

• Karnofsky-Index < 50 %

• known intolerance of erythropoietin

• FIGO stage IVB

• blood transfusion within the last four weeks

• neoadjuvant chemotherapy

• previous radiation therapy of the abdomen